SOPHiA GENETICS shows a confirmed technical breakout and favorable risk/reward asymmetry, but persistent cash burn, a Rule of 40 failure, and heavy insider selling activity weigh against the bullish technical setup.
Thesis pillars
- Elevated Options Hedging↑Improving
- Technical Breakout Golden Cross↑Improving
- Cash Burn Rule Of 40 Failure↑Improving
- +2 more pillars — see the Why tab for full reasoning
SOPHiA GENETICS SA (SOPH) Stock Analysis
Breakout setup
Healthcare · Health Information Services
Sell if holding. Engine safety override at $7.57: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: Below-average business quality.
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM... Read more
Sell if holding. Engine safety override at $7.57: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Score 5.7/10, moderate confidence.
Passes 6/9 gates (positive momentum, no SEC red flags, news events none recent, earnings proximity 82d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-08-13Recent Developments — SOPHiA GENETICS SA
Latest news
- NEWS HC Wainwright & Co. Maintains Buy on Sophia Genetics, Raises Price Target to $14 — benzinga Aug 5, 2026 neutral
- NEWS BTIG Maintains Buy on Sophia Genetics, Raises Price Target to $9 — benzinga Aug 5, 2026 positive
- NEWS Sophia Genetics Raises FY2026 Sales Guidance from $92.000M-$94.000M to $94.000M-$96.000M vs $93.403M Est — benzinga Aug 4, 2026 positive
- NEWS Sophia Genetics Q2 EPS $(0.30) Misses $(0.20) Estimate, Sales $23.310M Beat $21.729M Estimate — benzinga Aug 4, 2026 neutral
- NEWS SOPHiA GENETICS Announces Global Collaboration To Develop, Validate, And Deploy Two Companion Diagnostics Supporting Pre — benzinga Aug 4, 2026 positive
Generated 2026-08-14T11:47:20Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -93.9%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $7.57: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Prior stop was $7.04. Score 5.7/10, moderate confidence.
Take-profit target: $8.29 (+9.5% upside). Prior stop was $7.04. Stop-loss: $7.04.
Quality below floor (3.5 < 4.0).
SOPHiA GENETICS SA trades at a P/E of N/A (forward -15.2). TrendMatrix value score: 5.7/10. Verdict: Sell.
11 analysts cover SOPH with a consensus score of 4.3/5. Average price target: $10.
What does SOPHiA GENETICS SA do?SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM...
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom and a collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The company was incorporated in 2011 and is based in Rolle, Switzerland.